Home › Funds › Bruce & Co., Inc. › FATE

Bruce & Co., Inc. position in FATE

Fate Therapeutics Inc · Health Care

Bruce & Co., Inc. reported holding 989,188 shares of FATE (Fate Therapeutics Inc) in its Q2 2026 13F filing — a position valued at US$2.7M, representing 0.72% of its reported portfolio and ranking #28 among its reported holdings. Bruce & Co., Inc. has disclosed FATE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)989.19K sh
Reported value held$2.67M
Portfolio Weight0.72%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Bruce & Co., Inc.'s FATE position evolved

Bruce & Co., Inc. first disclosed a stake in FATE in Q3 2023 at 200,000 shares (US$424K). The position peaked in Q2 2026 at 989,188 shares, worth US$2.7M. Across 12 filings, Bruce & Co., Inc. increased the stake 6 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 989,188 shares valued at US$2.7M — an increase of 200,000 shares quarter over quarter.. Notable position changes include a 110% increase in Q2 2024 (shares rose 7% over the following quarter), a 57% increase in Q1 2025 (shares rose 42% over the following quarter), a 70% increase in Q3 2025 (shares fell 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 200.00K $424.00K New
Q4 2023 143.00K $534.82K Reduce
Q1 2024 143.00K $1.05M Hold
Q2 2024 300.00K $984.00K Add
Q3 2024 350.00K $1.23M Add
Q4 2024 350.00K $577.50K Hold
Q1 2025 550.00K $434.50K Add
Q2 2025 429.19K $480.69K Reduce
Q3 2025 729.19K $918.78K Add
Q4 2025 729.19K $716.50K Hold
Q1 2026 789.19K $947.03K Add
Q2 2026 989.19K $2.67M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About FATE and 13F data

FATE (Fate Therapeutics Inc) is a Health Care company. 18 other funds we track also report a position in FATE — the largest reported positions include Redmile Group, LLC (US$34.8M), JOHNSON & JOHNSON (US$9.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding FATE

All FATE fund holders →

FAQ

How long has Bruce & Co., Inc. held FATE?

Bruce & Co., Inc. has disclosed FATE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Bruce & Co., Inc.'s current position in FATE?

As of Q2 2026, Bruce & Co., Inc. holds 989.19K shares of FATE (Fate Therapeutics Inc), valued at $2.67M, representing 0.72% of its reported portfolio and ranking #28.

Has Bruce & Co., Inc. been buying or selling FATE?

In the latest 13F filing (Q2 2026), Bruce & Co., Inc. increased its position in FATE. The position peaked in Q2 2026 at 989.19K shares.

Which other funds hold FATE?

Other major institutional holders of FATE include Redmile Group, LLC, JOHNSON & JOHNSON, among 18 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.